|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Interest receivable | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Mortgage Loans Receivable, net of allowance for loan losses of $1,501,095 and $1,493,996 and deferred origination fees of $164,890 and $198,816 at March 31, 2021 and December 31, 2020, respectively | ||||||||||||||||||||
| Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss | ||||||||||||||||||||
| Bond Portfolio | ||||||||||||||||||||
| Real Estate Held for Sale | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Management fee payable | ||||||||||||||||||||
| Line of credit | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Secured Investor Certificates, Series B | ||||||||||||||||||||
| Secured Investor Certificates, Series C | ||||||||||||||||||||
| Secured Investor Certificates, Series D | ||||||||||||||||||||
| Secured Investor Certificates, Series E | ||||||||||||||||||||
| (Less) Deferred Offering Costs, net of accumulated amortization of $734,900 and $1,066,068 at March 31, 2021 and December 31, 2020, respectively | ||||||||||||||||||||
| Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Common Stock, Value, Issued | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...